Clearmind Medicine (CMND) EBITDA (2022 - 2026)

Clearmind Medicine (CMND) has reported EBITDA for 5 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 167.84% year-over-year to -$2.0 million; the trailing twelve-month figure through Apr 2026 stood at -$7.2 million (down 118.13% YoY), and the FY2025 full-year result was -$1.9 million, up 52.45% from the prior year.
• EBITDA improved to -$2.0 million in Q2 2026 per CMND's latest filing, from -$4.0 million in the prior quarter.
• Across five years, EBITDA topped out at $97087.0 in Q4 2024 and bottomed at -$6.4 million in Q4 2023.
• Historically, EBITDA has averaged -$1.5 million across 5 years, with a median of -$1.2 million in 2023.
• The widest YoY moves for EBITDA: up 101.52% in 2024, down 3303.43% in 2024.
• Over 5 years, EBITDA stood at -$1.5 million in 2022, then sank by 317.17% to -$6.4 million in 2023, then jumped by 101.52% to $97087.0 in 2024, then dropped by 12.49% to $84962.0 in 2025, then sank by 2506.18% to -$2.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.0 million, -$4.0 million, and $84962.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.